Immune Thrombocytopenia historical perspective

Jump to navigation Jump to search

Immune Thrombocytopenia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Immune Thrombocytopenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Immune Thrombocytopenia historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Immune Thrombocytopenia historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Immune Thrombocytopenia historical perspective

CDC on Immune Thrombocytopenia historical perspective

Immune Thrombocytopenia historical perspective in the news

Blogs on Immune Thrombocytopenia historical perspective

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Immune Thrombocytopenia historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Barkhordarian, M.D.[2]

Overview

Idiopathic Thrombocytopenia (ITP) was first described by a German poet Paul Werlhof, in 1735. He referred to classical signs of ITP as mucosal bleeding, black and purple spots on the patient's arm, due to this description, ITP is called Werlhof's disease.In 1881, an Italian pathologist, Guilio Bizzozero was the first to discover the role of platelet in hemostasis. In 1889, George Hayem proved the association between purpura and the development of thrombocytopenia by physically counting the patient's platelet. In 1916, a medical student Paul Kasnelson developed the idea of excessive destruction of platelets by spleen. Soon he persuaded his professor Schloffer to splectomize a patient with ITP, thereafter they found outstanding increase of platelet count following splenectomy. In 1951, Harrington experiment in Missouri proved the hypothesis that a humoral factor causes platelet destruction. He exchanged whole blood of himself and a patient with chronic purpura who had the same blood group. after the exchange, the patient platelet count remained unchanged but his platelet count which was normal prior to exchange dropped to 10 x 109 /L . In 1951, an American hematologist, Maxwell Wintrobe, showed immunosuppressive therapy with corticosteroids. In 1981, Paul Imbach in Switzerland, realized the role of Fc receptors on splenic macrophages led to first successful use of intravascular immunoglobulin. In 2009, International working group (IWG) recommended standard terminology for ITP. The term " purpura" was removed from immune thrombocytopenia as many patients don't have cutaneous bleeding but ITP as shorthand for immune thrombocytopenia was redefined by IWG.

Historical Perspective

Discovery

  • Idiopathic Thrombocytopenia (ITP) was first described by a German poet Paul Werlhof, in 1735. He referred to classical signs of ITP as mucosal bleeding, black and purple spots on the patient's arm, due to this description, ITP is called Werlhof's disease.
  • In 1881, an Italian pathologist, Guilio Bizzozero was the first to discover the role of platelet in hemostasis.
  • In 1889, George Hayem proved the association between purpura and the development of thrombocytopenia by physically counting the patient's platelet.
  • In 1916, a medical student Paul Kasnelson developed the idea of excessive destruction of platelets by spleen. Soon he persuaded his professor Schloffer to splectomize a patient with ITP, thereafter they found outstanding increase of platelet count following splenectomy.
  • In 1951, Harrington experiment in Missouri proved the hypothesis that a humoral factor causes platelet destruction. He exchanged whole blood of himself and a patient with chronic purpura who had the same blood group. after the exchange, the patient platelet count remained unchanged but his platelet count which was normal prior to exchange dropped to 10 x 109 /L .
  • in 1951, an American hematologist, Maxwell Wintrobe, showed immunosuppressive therapy with corticosteroids.
  • In 1981, Paul Imbach in Switzerland, realized the role of Fc receptors on splenic macrophages led to first successful use of intravascular immunoglobulin. [1]
  • In 2009, International working group (IWG) recommended standard terminology for ITP. The term " purpura" was removed from immune thrombocytopenia as many patients don't have cutaneous bleeding but ITP as shorthand for immune thrombocytopenia was redefined by IWG. [2]

Landmark Events in the Development of Treatment Strategies

Impact on Cultural History

Famous Cases

The following are a few famous cases of [disease name]:

References

  1. Anoop, P. (2012). "Immune thrombocytopenic purpura: Historical perspective, current status, recent advances and future directions". Indian Pediatrics. 49 (10): 811–818. doi:10.1007/s13312-012-0195-1. ISSN 0019-6061.
  2. Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes" Check |url= value (help). Biochem Pharmacol. 24 (17): 1639–41. PMID https://doi.org/10.1016/j.autrev.2014.01.026 Check |pmid= value (help).

Template:WH Template:WS